Sanjivani Paranteral Receives BSE Listing Approval for 1.97 Lakh Equity Shares Issued via Warrant Conversion

Sanjivani Paranteral Limited has announced that it has received formal listing approval from BSE Limited for 1,97,394 equity shares issued to its promoter on a preferential basis following the conversion of warrants. The approval was conveyed by BSE through its letter (Ref: LOD/PREF/PB/FIP/439/2025-26) dated 4th July 2025.

The newly listed equity shares have a face value of Rs. 10 each and were issued at a premium of Rs. 125.10 per share, demonstrating strong promoter commitment and capital infusion into the company.

Key Details of the Issue

According to the company’s disclosure to BSE under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the shares have been allotted with distinctive numbers ranging from 12079195 to 12276588.

This allotment follows the exercise of previously issued warrants, enabling the company to convert these into fully paid-up equity shares as part of its capital-raising strategy. The funds raised via this preferential issue are typically deployed for business expansion, working capital needs, or debt reduction, strengthening the company's balance sheet.

Preferential Allotment and Warrant Conversion Explained

A preferential issue is a mechanism under SEBI regulations allowing companies to raise capital by issuing shares to select investors, typically promoters or strategic partners, on preferential terms.

In this case, Sanjivani Paranteral had earlier issued warrants—convertible instruments granting the right to subscribe to equity shares at a pre-decided price. Upon conversion, the warrant-holder (the promoter in this instance) pays the agreed price (including premium) to receive the shares.

Such promoter-driven capital infusion is viewed by markets as a sign of promoter confidence in the company's prospects.

Regulatory Compliance and Disclosure

Sanjivani Paranteral’s disclosure confirms compliance with SEBI LODR Regulations, particularly Regulation 30, which mandates timely, material event disclosures to stock exchanges.

By publicly notifying BSE of the listing approval and enclosing the regulator’s confirmation letter, the company upholds transparency for its investors and stakeholders.

The disclosure also specifies the stock codes:

• BSE Scrip Code: 514322, 531569

Such filings ensure investors have clear, updated information about the company's capital structure and shareholding changes.

About Sanjivani Paranteral Limited

Sanjivani Paranteral Limited is an Indian company engaged in the manufacture and distribution of pharmaceutical and healthcare products. With its equity shares traded on BSE, the company adheres to stringent disclosure norms mandated for listed entities, reinforcing investor trust.

The fresh allotment following warrant conversion signals further capital strengthening and positions the company for future operational growth.

Looking Ahead

As Sanjivani Paranteral continues to pursue its growth plans, this capital infusion via warrant conversion is expected to augment resources and improve financial flexibility. Investors will watch closely for further updates on how these funds are deployed to enhance business performance.

The Upcoming IPOs in this week and coming weeks are Asston Pharmaceuticals, CFF Fluid Control, Smarten Power Systems, Glen Industries, Travel Food Services, Anthem Biosciences, Chemkart India.

The Current active IPO are Meta Infotech, Happy Square Outsourcing Services, Cryogenic OGS.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.